· Circio has been selected to present its circVec circular RNA expression
platform at the European Society of Cell and Gene Therapy (ESGCT) annual meeting
2024, taking place on 22-25 October 2024 in Rome, Italy
  · ESGCT is one of the most prestigious and widely attended international
conferences in the gene therapy field
  · In the presentation, Circio wil showcase the latest developments and in vivo
data for its circVec circular RNA expression platform designed to enhance gene
therapy

Oslo, Norway 24 September 2024 - Circio Holding ASA (OSE: CRNA), a biotechnology
company developing next generation circular RNA vector technology for gene
therapy, today announces that a scientific abstract submitted to the European
Society of Cell and Gene Therapy (ESGCT) annual meeting 2024 has been selected
for oral presentation. The presentation will be given by CircioŽs CTO, Dr.
Thomas B Hansen on 23 October 2024.

"CircioŽs unique and powerful circVec platform keeps building momentum, and we
are very excited to be selected to present our technology at the prestigious
ESGCT meeting." said Dr. Thomas B. Hansen, CTO of Circio  "This meeting provides
a great opportunity to showcase how the latest circVec generation continues to
significantly outperform mRNA-based expression, thereby delivering a substantial
improvement over current gold-standard gene therapy approaches."

The ESGCT invitation follows recent presentations at several RNA industry
conferences and coverage in international life science media, highlighting the
advantages and potential of circular RNA therapeutics and reinforcing CircioŽs
position as a leader in this rapidly emerging field.

Title of presentation:

Optimization of in vitro and in vivo performance of circVec, a vector-based
circular RNA expression platform for enhanced gene therapy

Presenter:

Dr. Thomas B Hansen, CTO

Time and location:

23 October 2024 @ 19:30hrs CET - Rome, Italy

For further information, please contact:
Erik Digman Wiklund, CEO
Phone: +47 413 33 536
Email: erik.wiklund@circio.com

About Circio

Building next generation RNA therapeutics

Circio Holding ASA is a biotechnology company developing novel circular RNA and
immunotherapy medicines.

Circio has established a unique circular RNA (circRNA) platform for genetic
medicine. The proprietary circVec technology is based on a modular genetic
cassette design for efficient biogenesis of multifunctional circRNA from DNA and
viral vectors, which can be deployed in multiple disease settings. The circVec
platform has demonstrated enhanced and more durable protein expression than
classic mRNA vector systems, and has the potential to become the new gold
-standard for DNA and virus-based therapeutics in the future. The circRNA R&D
activities are being conducted by the wholly owned subsidiary Circio AB based at
the Karolinska Institute in Stockholm, Sweden.